低剂量地西他滨对比低剂量阿扎胞苷治疗较低危MDS及MDS/MPN的随机2期研究
该随机2期研究纳入113例较低危MDS或MDS/MPN成人患者,按贝叶斯自适应设计分配接受低剂量阿扎胞苷(40例)或低剂量地西他滨(73例)。地西他滨组总缓解率70%、阿扎胞苷组49%(P=0.03),细胞遗传学缓解率分别为61%和25%(P=0.02);6周死亡率为0%。
要点
- 地西他滨组总缓解率70%,阿扎胞苷组49%(P=0.03)。
- 地西他滨组细胞遗传学缓解率61%,阿扎胞苷组25%(P=0.02)。
- 中位随访20个月,总中位无事件生存期18个月。
核心结论
- 低剂量去甲基化药物在较低危MDS及MDS/MPN患者中安全有效。
- 其对较低危疾病自然病程的影响需进一步研究。
研究设计与样本
- 随机2期研究,采用贝叶斯自适应设计,比较低剂量地西他滨与低剂量阿扎胞苷。
- 纳入根据国际预后评分系统为低危或中危1的MDS或MDS/MPN(含慢性粒单核细胞白血病)成人患者。
- 2012年11月至2016年2月共治疗113例:阿扎胞苷组40例(35%),地西他滨组73例(65%)。
- 中位年龄70岁;81%为中危1患者;中位接受9个周期。
- 阿扎胞苷75 mg/m2静脉/皮下每日给药;地西他滨20 mg/m2静脉每日给药,连续3天,28天为一周期。
主要发现
- 总缓解率:地西他滨组70% vs 阿扎胞苷组49%(P=0.03)。
- 脱离输血:地西他滨组32% vs 阿扎胞苷组16%(P=0.2)。
- 细胞遗传学缓解率:地西他滨组61% vs 阿扎胞苷组25%(P=0.02)。
- 中位随访20个月,总中位无事件生存期18个月;地西他滨组20个月 vs 阿扎胞苷组13个月(P=0.1)。
- 治疗耐受良好,6周死亡率为0%。
关键数值与推荐
- 总缓解率:地西他滨组70% vs 阿扎胞苷组49%(P=0.03)。
- 细胞遗传学缓解率:地西他滨组61% vs 阿扎胞苷组25%(P=0.02)。
- 脱离输血:地西他滨组32% vs 阿扎胞苷组16%(P=0.2)。
- 中位无事件生存期:地西他滨组20个月 vs 阿扎胞苷组13个月(P=0.1)。
- 6周死亡率为0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 其对较低危疾病自然病程的影响需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypomethylating agents (HMAs) improve survival in patients with higher-risk myelodysplastic syndromes (MDS) but are less well-studied in lower-risk disease. We compared the safety and efficacy of low-dose decitabine vs low-dose azacitidine in this group of patients. Adults with low- or intermediate 1-risk MDS or MDS/myeloproliferative neoplasm (MPN), including chronic myelomonocytic leukemia, according to the International Prognostic Scoring System, were randomly assigned using a Bayesian adaptive design to receive either azacitidine 75 mg/m2 intravenously/subcutaneously daily or decitabine 20 mg/m2 intravenously daily for 3 consecutive days on a 28-day cycle. The primary outcome was overall response rate (ORR). Between November 2012 and February 2016, 113 patients were treated: 40 (35%) with azacitidine and 73 (65%) with decitabine. The median age was 70 years; 81% of patients were intermediate 1-risk patients. The median number of cycles received was 9. The ORRs were 70% and 49% (P = .03) for patients treated with decitabine and azacitidine, respectively. Thirty-two percent of patients treated with decitabine became transfusion independent compared with 16% of patients treated with azacitidine (P = .2). Cytogenetic response rates were 61% and 25% (P = .02), respectively. With a median follow-up of 20 months, the overall median event-free survival was 18 months: 20 and 13 months for patients treated with decitabine and azacitidine, respectively (P = .1). Treatment was well tolerated, with a 6-week mortality rate of 0%. The use of low-dose HMAs is safe and effective in patients with lower-risk MDS and MDS/MPN. Their effect on the natural history of lower-risk disease needs to be further studied. This trial was registered at clinicaltrials.gov (identifier NCT01720225).
引用
- Jabbour E, Short NJ, Montalban-Bravo G, et al. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017. PMID: 28774880. doi:10.1182/blood-2017-06-788497
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。